Update on Erythropoiesis-Stimulating Agents Administered to Neonates for Neuroprotection.


Journal

NeoReviews
ISSN: 1526-9906
Titre abrégé: Neoreviews
Pays: United States
ID NLM: 101085360

Informations de publication

Date de publication:
11 2019
Historique:
entrez: 3 11 2019
pubmed: 5 11 2019
medline: 20 8 2020
Statut: ppublish

Résumé

Erythropoiesis-stimulating agents (ESAs) such as erythropoietin and darbepoetin have been studied as red blood cell growth factors in preterm and term infants for more than 30 years. Recently, studies have focused on the potential neuroprotective effects of ESAs. In this review, we summarize preclinical animal models and recent clinical trials that provide evidence for ESAs as potential treatments to improve neurodevelopmental outcomes in preterm and term infants.

Identifiants

pubmed: 31676737
pii: 20/11/e622
doi: 10.1542/neo.20-11-e622
doi:

Substances chimiques

Hematinics 0
Neuroprotective Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e622-e635

Informations de copyright

Copyright © 2019 by the American Academy of Pediatrics.

Auteurs

Jessie R Maxwell (JR)

Department of Pediatrics, University of New Mexico, Albuquerque, NM.

Robin K Ohls (RK)

Department of Pediatrics, University of Utah, Salt Lake City, UT.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH